FeesSafety
Pluang+

Zealand Pharma starts Phase 2 trial of petrelintide and enicepatide combo for obesity treatment

Company Fundamentals
18 Nov 2026, 08:00 WIB
GlobeNewsWire
View Source
Bullish
Zealand Pharma starts Phase 2 trial of petrelintide and enicepatide combo for obesity treatment

Zealand Pharma has initiated the Phase 2 ZYNERGY trial to test the safety and effectiveness of petrelintide combined with enicepatide in people with obesity or overweight with related health issues. The trial will evaluate three dosing regimens over 40 weeks, aiming to achieve significant weight loss and improve cardiometabolic risk markers while maintaining good tolerability. This study follows promising results from earlier trials and supports dose selection for Phase 3 development. The trial will enroll 480 participants and compare the combination therapy against placebo and monotherapies.

Zealand Pharma's new Phase 2 trial of petrelintide with enicepatide offers context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 18, 2026 13:11 WIB: out of 150 priced US health-sector stocks, 42 rose and 107 fell. Notable movers include MMED at USD 17.74 with a 1-day change of -4.88% and 100% buy order activity, HNGE at USD 115.50 down 4.77%, and MESO at USD 11.86 down 4.74%.

More News

ZTO Express beats Q3 earnings and revenue estimates with 21% revenue growth and rising parcel volume.

ZTO Express beats Q3 earnings and revenue estimates with 21% revenue growth and rising parcel volume.

ZTO Express (Cayman) Inc. reported Q3 2026 earnings per share of $0.48, surpassing estimates of $0.4665, and revenue of $2.14 billion, exceeding the $2.08 billion forecast. The company saw a 21% year-over-year revenue increase to CNY 14.4 billion and...

Company Fundamentals
Bullish
2 hours ago
Temporal launches Supermassive, a fully onchain perpetual futures exchange on Solana, debuting in January 2027.

Temporal launches Supermassive, a fully onchain perpetual futures exchange on Solana, debuting in January 2027.

Temporal announced Supermassive, a new perpetual futures exchange built entirely on Solana's blockchain, set to launch on mainnet in January 2027. This platform separates trading and clearing, allowing multiple venues and market makers to compete for...

Market News
Bullish
4 hours ago
UFP Industries stock steady at 2022 price despite earnings drop and margin pressure.

UFP Industries stock steady at 2022 price despite earnings drop and margin pressure.

UFP Industries' stock remains around $79, close to its 2022 closing price, even though earnings per share (EPS) have fallen significantly from $10.97 to $4.12. Third-quarter sales increased by 11.1%, but higher freight costs compressed profit margins...

Company Fundamentals
Bearish
5 hours ago
Oil prices dip on rising US crude stocks amid US-Iran tensions and regional attacks.

Oil prices dip on rising US crude stocks amid US-Iran tensions and regional attacks.

Oil prices slipped as US crude and fuel inventories increased, signaling softer near-term demand. However, ongoing military tensions between the US and Iran, including drone attacks and missile strikes, limited the price decline. Additional risks fro...

Market News
Bearish
5 hours ago
Upbit partners with Ammora to boost Frax USD liquidity in South Korea's DeFi market

Upbit partners with Ammora to boost Frax USD liquidity in South Korea's DeFi market

Upbit has formed a partnership with Ammora, a liquidity protocol developed by GIWA, to enhance liquidity for Frax USD (frxUSD) within South Korea's decentralized finance (DeFi) sector. This collaboration aims to strengthen the availability and tradin...

Protocol Fundamentals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App